The pharmacological treatment of schizophrenia: How far have we come?-Reference-Cited by-同舟云学术

The pharmacological treatment of schizophrenia: How far have we come?

Published:2022-05-30 Issue:2 Volume:1 Page:
ISSN:2769-2558
Container-title:Psychiatry and Clinical Neurosciences Reports
language:en
Short-container-title:PCN Reports

Author:

Rubio Jose M.¹^ORCID,Kane John M.¹^ORCID

Affiliation:

1. Donald and Barbara Zucker School of Medicine at Hofstra—Northwell, Feinstein Institutes of Medical Research—Institute of Behavioral Science Zucker Hillside Hospital—Northwell Health Glen Oaks NY United States

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pcn5.13

Reference111 articles.

1. Schizophrenia—An Overview

2. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016

3. Comorbidities and Mortality in Persons With Schizophrenia: A Swedish National Cohort Study

4. Sixty Years of Placebo-Controlled Antipsychotic Drug Trials in Acute Schizophrenia: Systematic Review, Bayesian Meta-Analysis, and Meta-Regression of Efficacy Predictors

5. A recovery-oriented service system: Setting some system level standards.

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Investigating Cannabidiol's potential as a supplementary treatment for schizophrenia: A narrative review;European Journal of Pharmacology;2024-09

2. Therapeutic potential of gamma entrainment using sensory stimulation for cognitive symptoms associated with schizophrenia;Neuroscience & Biobehavioral Reviews;2024-06

3. Active Lifestyle in Schizophrenia;Combining Exercise and Psychotherapy to Treat Mental Health;2023-11-28

4. Second International Consensus Study of Antipsychotic Dosing (ICSAD-2);Journal of Psychopharmacology;2023-10

5. Inhibitors of Endocannabinoids’ Enzymatic Degradation as a Potential Target of the Memory Disturbances in an Acute N-Methyl-D-Aspartate (NMDA) Receptor Hypofunction Model of Schizophrenia in Mice;International Journal of Molecular Sciences;2023-07-13